Galinpepimut-S shows a 41% reduction in risk of death in Phase 3 AML trial

SELLAS Life Sciences Group has reported positive topline results from its pivotal Phase 3 REGAL trial, in which its investigational WT1-targeted immunotherapeutic vaccine galinpepimut-S (GPS) met the primary endpoint of overall survival in patients with acute myeloid leukaemia (AML). The treatment was associated with a 41% reduction in the risk of death compared with best available treatment, with median overall survival of 24.0 months versus 14.7 months.

Phase 3 REGAL trial demonstrates an overall survival benefit

The global, randomised, open-label REGAL trial evaluated galinpepimut-S as maintenance monotherapy in patients with AML who had achieved a second or subsequent complete remission (CR2 or later), or complete remission with insufficient platelet recovery (CRp2 or later), following second-line or later salvage therapy.

A total of 126 patients were randomised, all of whom were ineligible for, or unable to undergo, allogeneic haematopoietic stem cell transplantation. Participants were randomised in a 1:1 ratio to receive either GPS monotherapy or the investigator’s choice of best available treatment (BAT).

The primary endpoint was overall survival, measured from study entry. The primary analysis was conducted after the pre-specified 80th death had occurred, in accordance with the trial’s statistical analysis plan.

The topline results showed:

  • 41% reduction in the risk of death: hazard ratio (HR) of 0.59, with a two-sided p-value of 0.035.
  • Median overall survival: 24.0 months in the GPS group compared with 14.7 months in the BAT group, representing a difference of 9.3 months.
  • Balanced treatment groups: the company reported that both arms were well balanced for prognostic stratification factors. The small number of patients who subsequently underwent haematopoietic stem cell transplantation was equally distributed between the groups.

These results indicate that the study met its primary endpoint, demonstrating a statistically significant overall survival advantage for GPS in the patient population studied.

The figures represent topline results announced by SELLAS. Full statistical analyses are still ongoing, and the findings have not yet been published in a peer-reviewed journal.

WT1-targeted immunotherapy

Galinpepimut-S is an investigational, off-the-shelf peptide-based immunotherapeutic vaccine targeting Wilms’ tumour 1 (WT1), a protein expressed in a range of haematological malignancies and solid tumours, including AML.

The candidate was discovered in the laboratory of David A. Scheinberg and is licensed from Memorial Sloan Kettering Cancer Center.

GPS consists of four WT1-derived peptides designed to stimulate both CD4+ helper T-cell and CD8+ cytotoxic T-cell responses across multiple human leukocyte antigen (HLA) types.

The proposed mechanism involves activating the patient’s immune system to recognise and target residual WT1-expressing leukaemic cells. The vaccine is being investigated as a maintenance treatment intended to prolong remission and improve survival.

Safety findings

According to SELLAS, GPS was generally well tolerated, with a safety profile consistent with previous clinical experience and no new safety signals identified.

Treatment-related adverse events were predominantly mild to moderate (Grade 1–2). The most frequently reported events were local injection-site reactions.

The company also reported that the limited number of patients who proceeded to haematopoietic stem cell transplantation was equally distributed between the study groups.

Detailed safety findings have not yet been presented in a full publication of the clinical results.

Regulatory pathway and further clinical data

Following the positive topline results, SELLAS plans to engage with the US Food and Drug Administration (FDA) to discuss an accelerated regulatory filing strategy.

The company is advancing preparations for a Biologics License Application (BLA) submission for galinpepimut-S in the first half of 2027. This timeline remains subject to discussions with the FDA and further assessment of the clinical data.

Comprehensive analyses of secondary endpoints and other pre-specified assessments are ongoing. These include:

  • Leukaemia-free survival.
  • Measurable residual disease (MRD).
  • Antigen-specific T-cell immune response dynamics.
  • Safety and tolerability.
  • Landmark overall survival.
  • Relapse-free survival in patients with prior allogeneic transplantation.
  • Other molecular and clinical assessments.

SELLAS plans to present detailed findings at an upcoming major medical congress and submit the results for publication in a peer-reviewed scientific journal.

The REGAL findings represent an important clinical development milestone for WT1-targeted immunotherapy in AML. Further evaluation of the complete dataset will be important for assessing the potential role of galinpepimut-S in maintenance treatment and its prospects for regulatory approval.

POPULAR